Browsing Category
Pharma Industry News
4750 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How Shift Bioscience is using AI and cell reprogramming to target aging at its core
Discover how Shift Bioscience is redefining longevity science with AI and cell rejuvenation—now backed by top-tier leadership from UK healthcare and research.
REGENXBIO monetizes gene therapy royalties in $250m deal with HCRx
REGENXBIO advances strategic funding deal with Healthcare Royalty to monetize Zolgensma and pipeline royalties while preserving upside from NAV platform assets and AbbVie/Nippon Shinyaku partnerships.
Novavax shares rally after FDA approves non-mRNA COVID-19 vaccine for at-risk groups
Novavax stock surged 25% after FDA approved its non-mRNA COVID-19 vaccine Nuvaxovid. Find out what triggered this rally and what it means for investors.
Regeneron to acquire 23andMe’s core assets for $256m amid court-supervised bankruptcy sale
Regeneron to acquire 23andMe’s core assets for $256M in a court-supervised deal. Learn how this biotech merger impacts DNA data privacy, investor sentiment, and the future of genetics.
Salesforce and Takeda partner to transform pharma engagement with AI-driven Life Sciences Cloud platform
Discover how Salesforce and Takeda are redefining pharma engagement using AI-powered Life Sciences Cloud. Learn how data, AI, and patient outcomes align.
Halozyme Therapeutics stock rises 6.27% after beating Q1 expectations, raising 2025 outlook
Halozyme Therapeutics stock rose as Q1 earnings beat expectations and 2025 guidance improved. See how ENHANZE® drives royalty growth and future prospects.
How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment?
Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now.
Be Biopharma reports positive preclinical data for BE-102 in hypophosphatasia
Be Biopharma shares preclinical results for BE-102, a B cell medicine in development for treating hypophosphatasia. Read about its novel approach.
Apellis Pharmaceuticals gains 6.66% as investors bet on Q2 trial update and long-term pipeline potential
Apellis Pharmaceuticals stock jumped 6.66% as investors bet on key trial updates and undervalued biotech potential. Will FDA decisions drive more upside?
CRISPR Therapeutics stock jumps 6.77% as institutional rebalancing favors gene-editing names
CRISPR Therapeutics stock rose 6.77% as funds rotated back into gene-editing names. Find out what’s driving the rebound and what lies ahead for CRSP.